Strategies Needed for Resistance to Targeted Agents in HER2 Breast Cancer

Strategies Needed for Resistance to Targeted Agents in HER2+ Breast Cancer

12:44 EST 15 Jan 2019 | OncLive

Mothaffar F. Rimawi, MD, discusses the current options in HER2-positive breast cancer and sheds light on where future research is headed.

More From BioPortfolio on "Strategies Needed for Resistance to Targeted Agents in HER2+ Breast Cancer"